Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study
Authors' conclusion
Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.
Study context
- Population
- Youths (age 10–18 years) with T2D enrolled in a completed placebo-controlled glycemic control trial of dulaglutide
- Participants
- 154 participants
- Comparison
- Dulaglutide vs placebo
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Change in mean eGFR · baseline to 26 weeks
Dulaglutide
−5.8
mean · mL/min/1.73 m²
Placebo
−0.1
mean · mL/min/1.73 m²
P = 0.016
Further findings
| Outcome | P value |
|---|---|
| Prevalence of glomerular hyperfiltration · 26 weeksIncreased with placebo, decreased with dulaglutide | P = 0.014 |
| Prevalence of proteinuria · 26 weeksIncreased with placebo, decreased with dulaglutide | P = 0.004 |
Original publication
Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. Published 2 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →